Flexion Therapeutics, Inc. (FLXN) Insider Yamo Deniz Acquires 1,375 Shares

Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Yamo Deniz bought 1,375 shares of Flexion Therapeutics stock in a transaction that occurred on Thursday, August 31st. The shares were acquired at an average price of $25.40 per share, with a total value of $34,925.00. Following the completion of the transaction, the insider now owns 5,000 shares of the company’s stock, valued at $127,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Yamo Deniz also recently made the following trade(s):

  • On Tuesday, September 5th, Yamo Deniz bought 1,000 shares of Flexion Therapeutics stock. The shares were acquired at an average price of $24.20 per share, with a total value of $24,200.00.
  • On Friday, September 1st, Yamo Deniz bought 3,000 shares of Flexion Therapeutics stock. The shares were acquired at an average price of $24.15 per share, with a total value of $72,450.00.

Shares of Flexion Therapeutics, Inc. (FLXN) traded up 2.16% during midday trading on Friday, reaching $24.12. The company’s stock had a trading volume of 732,733 shares. The company’s 50-day moving average price is $23.25 and its 200-day moving average price is $22.01. The company’s market cap is $769.55 million. Flexion Therapeutics, Inc. has a 12 month low of $15.93 and a 12 month high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). On average, equities analysts anticipate that Flexion Therapeutics, Inc. will post ($3.70) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Flexion Therapeutics, Inc. (FLXN) Insider Yamo Deniz Acquires 1,375 Shares” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/09/16/flexion-therapeutics-inc-flxn-insider-yamo-deniz-acquires-1375-shares.html.

Several equities analysts recently commented on FLXN shares. Cantor Fitzgerald set a $40.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a research report on Monday, May 22nd. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. BMO Capital Markets restated a “buy” rating on shares of Flexion Therapeutics in a research report on Tuesday, June 27th. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Royal Bank Of Canada restated a “buy” rating and set a $44.00 target price on shares of Flexion Therapeutics in a research report on Friday, July 7th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $31.50.

Institutional investors have recently modified their holdings of the company. Fiduciary Trust Co. purchased a new position in shares of Flexion Therapeutics during the second quarter valued at about $101,000. IFP Advisors Inc grew its position in shares of Flexion Therapeutics by 24.5% during the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,000 shares in the last quarter. Advisor Group Inc. grew its position in shares of Flexion Therapeutics by 205.9% during the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares in the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Flexion Therapeutics during the first quarter valued at about $319,000. Finally, Voya Investment Management LLC grew its position in shares of Flexion Therapeutics by 25.8% during the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after purchasing an additional 2,651 shares in the last quarter. Hedge funds and other institutional investors own 82.75% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply